Cardiac and renal complications of carfilzomib in patients with multiple myeloma-Reference-Cited by-同舟云学术

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Published:2017-02-27 Issue:7 Volume:1 Page:449-454
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Dimopoulos Meletios A.¹^ORCID,Roussou Maria¹,Gavriatopoulou Maria¹,Psimenou Erasmia¹,Ziogas Dimitrios¹,Eleutherakis-Papaiakovou Evangelos¹,Fotiou Despina¹,Migkou Magdalini¹,Kanellias Nikolaos¹,Panagiotidis Ioannis¹,Ntalianis Argyrios¹,Papadopoulou Elektra¹,Stamatelopoulos Kimon¹,Manios Efstathios¹,Pamboukas Constantinos¹,Kontogiannis Sofoklis¹,Terpos Evangelos¹,Kastritis Efstathios¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Key Points Carfilzomib is associated with reversible cardiotoxicity in 12% of consecutive myeloma patients. Transient renal toxicity is common, but carfilzomib may improve renal function in myeloma-related renal impairment.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/7/449/878156/advances003269.pdf

Reference32 articles.

1. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome;Demo;Cancer Res,2007

2. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events;Arastu-Kapur;Clin Cancer Res,2011

3. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma;Lendvai;Blood,2014

4. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma;Siegel;Blood,2012

5. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies;Siegel;Haematologica,2013

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-19

2. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium;Journal of Thrombosis and Haemostasis;2024-07

4. Management of hematological patients requiring emergency chemotherapy in the intensive care unit;Intensive Care Medicine;2024-05-15

5. Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3/NF-κB and PI3K/Akt/GSK-3β/MAPK axes;Life Sciences;2023-12